Abstract 183P
Background
In Asia, the standard treatment for locally advanced gastric cancer (LAGC) involves gastrectomy with D2 dissection and adjuvant chemotherapy. However, achieving adequate chemotherapy intensity after gastrectomy presents challenges. Previous trials have shown the effectiveness of neoadjuvant chemotherapy (NAC). Nevertheless, limited research has been conducted to explore the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) aimed to assess the safety and efficacy of NAC-SOX in LAGC patients aged ≥ 70 years. Herein, we present the conclusive data analysis of KSCC1801, shedding light on its outcomes.
Methods
Patients received NAC consisting of three cycles of SOX130 (oxaliplatin 130 mg/m2 on day 1, oral S-1 40-60 mg twice daily for two weeks every three weeks), followed by gastrectomy with lymph node dissection. The primary endpoint was the dose intensity (DI) of the treatment. Secondary endpoints included safety, R0 resection rate, pathological response rate (pRR), overall survival, and relapse-free survival.
Results
The study enrolled 26 patients with a median age of 74.5 years. The median DI in the NAC-SOX130 treatment was 97.2% for S-1 and 98.3% for oxaliplatin. NAC was successfully administered to 25 patients (96.2%), among whom 24 (92.3%) underwent gastrectomy with lymphadenectomy. The R0 resection rate was 92.3%, and the pRR (≥ grade 1b) was 62.5%. Major adverse events (≥ grade 3) included neutropenia (20.0%), thrombocytopenia (11.5%), anorexia (11.5%), nausea (7.7%), and hyponatremia (7.7%). Postoperative complications such as abdominal infection, elevated blood amylase, and bacteremia occurred in one patient each. The 1- and 2-year OS rates were 93.3% and 89.7%, respectively. The 1- and 2-year RFS rates were 68.7% and 58.6%, respectively.
Conclusions
NAC-SOX130 proves to be a feasible therapy for older patients aged ≥ 70 years.
Clinical trial identification
jRCTs071180001.
Editorial acknowledgement
Legal entity responsible for the study
KSCC (Kyushu Study group of Clinical Cancer).
Funding
Yakult Honsha.
Disclosure
E. Oki: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bayer, Eli Lilly, Bristol-myers Squibbb, MSD; Financial Interests, Personal and Institutional, Research Grant: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract